Management tracks: Partner Therapeutics, Merck
Robert Mulroy and Debasish Roychowdhury launched newco Partner Therapeutics Inc. (Boston, Mass.), which has a portfolio of approved and late-stage cancer therapies. Chairman and CEO Mulroy was co-founder, CEO and president of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK). CMO Roychowdhury was CMO of Seragon Pharmaceuticals Inc., which Roche (SIX:ROG; OTCQX:RHHBY) acquired.
Merck & Co. Inc. (NYSE:MRK) hired Fiona Marshall as head of its new discovery research center in the U.K. She was EVP and CSO at Sosei Group Corp. (Tokyo:4565) and a founder of Heptares Therapeutics Ltd., which Sosei acquired in 2015. In Nov. 2017, Merck announced plans to establish a London-based life sciences discovery research facility, intended to become the pharma's U.K. headquarters, with a launch date of 2020...